Literature DB >> 9407246

Inhaled nitric oxide in patients with pulmonary embolism.

G Capellier1, T Jacques, P Balvay, G Blasco, E Belle, F Barale.   

Abstract

OBJECTIVE: To describe the use of inhaled nitric oxide (NO) in four patients with severe pulmonary embolism.
SETTING: The intensive care unit (ICU) of a university teaching hospital. PATIENTS: Four patients with severe pulmonary embolism on the basis of clinical, haemodynamic or blood-gas parameters received NO by inhalation either during spontaneous respiration (two cases) or while mechanically ventilated (two cases).
INTERVENTIONS: Conventional management of pulmonary embolism in addition to the use of inhaled NO. MEASUREMENTS AND
RESULTS: Description of clinical course, haemodynamic and gas-exchange data. Dose-response data are also described for three patients.
CONCLUSIONS: We reported four cases of pulmonary embolism where the administration of inhaled NO resulted in an improvement in pulmonary haemodynamic and gas-exchange parameters. Two patients were weaned from NO and survived until discharged from the ICU. Inhaled NO might be a useful adjunct in pulmonary embolism to improve stability of the patient prior to thrombolysis or surgery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407246     DOI: 10.1007/s001340050461

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  16 in total

1.  The effect of a combination of inhaled nitric oxide and an endothelinA-receptor antagonist on hemodynamic dysfunction in experimental acute pulmonary thromboembolism.

Authors:  Ji-Hyun Lee; Sehyun Kim; Byung-Kyu Park; Woo-Sung Kim; Dong-Soon Kim; Won-Dong Kim; Sang-Do Lee
Journal:  Lung       Date:  2005 Mar-Apr       Impact factor: 2.584

2.  Inhaled nitric oxide therapy in adults: European expert recommendations.

Authors:  Peter Germann; Antonio Braschi; Giorgio Della Rocca; Anh Tuan Dinh-Xuan; Konrad Falke; Claes Frostell; Lars E Gustafsson; Philippe Hervé; Philippe Jolliet; Udo Kaisers; Hector Litvan; Duncan J Macrae; Marco Maggiorini; Nandor Marczin; Bernd Mueller; Didier Payen; Marco Ranucci; Dietmar Schranz; Rainer Zimmermann; Roman Ullrich
Journal:  Intensive Care Med       Date:  2005-06-23       Impact factor: 17.440

3.  Increased expired NO and roles of CO2 and endogenous NO after venous gas embolism in rabbits.

Authors:  Per Agvald; L Christofer Adding; Kristofer F Nilsson; Lars E Gustafsson; Dag Linnarsson
Journal:  Eur J Appl Physiol       Date:  2006-04-21       Impact factor: 3.078

4.  Inhaled nitric oxide and pulmonary embolism.

Authors:  J E Tanus-Santos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

5.  Inhaled nitric oxide in patients with pulmonary embolism.

Authors:  J E Tulleken; T S van der Werf; J G Zijlstra; G Capellier; T Jacques; P Balvay; F Barale
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 6.  Acute lung failure.

Authors:  Rob Mac Sweeney; Daniel F McAuley; Michael A Matthay
Journal:  Semin Respir Crit Care Med       Date:  2011-10-11       Impact factor: 3.119

7.  No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial.

Authors:  Albertus J Kooter; Richard G Ijzerman; Otto Kamp; Anco B Boonstra; Yvo M Smulders
Journal:  BMC Pulm Med       Date:  2010-03-30       Impact factor: 3.317

8.  Treatment of Submassive Pulmonary Embolism: Knowing When to be Aggressive and When to be Conservative.

Authors:  David L Ain; Michael R Jaff
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

Review 9.  [Pulmonary embolism].

Authors:  M Hecker; N Sommer; A Hecker; D Bandorski; M A Weigand; G A Krombach; E Mayer; D Walmrath
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-11-30       Impact factor: 0.840

10.  Decision for aggressive therapy in acute pulmonary embolism: implication of elevated troponin T.

Authors:  Felix Post; Dirk Mertens; Christoph Sinning; Dirk Peetz; Thomas Münzel
Journal:  Clin Res Cardiol       Date:  2009-04-09       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.